A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 1, Pages 218-229
Publisher
Springer Nature
Online
2014-05-14
DOI
10.1038/leu.2014.159
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasticity in programming of effector and memory CD8+T-cell formation
- (2015) Ramon Arens et al. IMMUNOLOGICAL REVIEWS
- Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma
- (2013) Sagar Lonial et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
- (2013) Benjamin M. Cherry et al. LEUKEMIA & LYMPHOMA
- Immunomodulatory drugs in multiple myeloma
- (2013) Swati Andhavarapu et al. Expert Review of Hematology
- A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
- (2012) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes
- (2012) Sergio Rutella et al. Clinical & Developmental Immunology
- Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
- (2012) J. Bae et al. CLINICAL CANCER RESEARCH
- Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease
- (2012) A. Agarwal et al. CLINICAL CANCER RESEARCH
- Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
- (2012) Kimberly Noonan et al. CLINICAL CANCER RESEARCH
- Immunotherapy of Cancer with 4-1BB
- (2012) D. S. Vinay et al. MOLECULAR CANCER THERAPEUTICS
- Redefining myeloma
- (2012) S. Vincent Rajkumar et al. Nature Reviews Clinical Oncology
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
- (2012) Caroline Rousseau et al. TUMOR BIOLOGY
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
- (2011) N. Korde et al. BLOOD
- Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders
- (2011) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vaccines for Colorectal Cancer and Renal Cell Carcinoma
- (2011) Katherine Kabaker et al. CANCER JOURNAL
- Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures
- (2011) Niels Junker et al. CELLULAR IMMUNOLOGY
- Vaccination Strategies in Lymphomas and Leukaemias
- (2011) Katayoun Rezvani et al. DRUGS
- Keeping STATs on Memory CD8+ T Cells
- (2011) Janelle A. Olson et al. IMMUNITY
- Opposing Signals from the Bcl6 Transcription Factor and the Interleukin-2 Receptor Generate T Helper 1 Central and Effector Memory Cells
- (2011) Marion Pepper et al. IMMUNITY
- Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma
- (2011) J Bae et al. LEUKEMIA
- Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?
- (2011) M. Tucci et al. ONCOLOGIST
- Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
- (2010) I. Papandreou et al. BLOOD
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- (2010) M. K. Brimnes et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
- (2009) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
- A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients
- (2009) Klaudia Kuranda et al. EXPERIMENTAL HEMATOLOGY
- Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses
- (2009) Axel Kallies et al. IMMUNITY
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
- (2009) Luca Gattinoni et al. NATURE MEDICINE
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- (2008) B. Barlogie et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
- (2008) G. G. Kenter et al. CLINICAL CANCER RESEARCH
- Ag-Specific Type 1 CD8 Effector Cells Enhance Methotrexate-Mediated Antitumor Responses by Modulating Endogenous CD49b-Expressing CD4 and CD8 T Effector Cell Subpopulations Producing IL-10
- (2008) Mark J. Dobrzanski et al. IMMUNOLOGICAL INVESTIGATIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search